Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Retrospect Stage IND EXEMPT Clinical Study - Etoposide and Single Nucleotide Polymorphisms (Drugs-SNPs)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Dr. Han Xu, President/CEO / PD / PI / Monitor / IRB Chair, Medicine Invention Design, Inc
ClinicalTrials.gov Identifier:
NCT01064466
First received: February 2, 2010
Last updated: August 6, 2016
Last verified: August 2016